Part VI: Summary of the risk management plan

Summary of risk management plan for

Tofacitinib STADA 5 mg & 10 mg tabletti, kalvopäällysteinen;
Tofacitinib STADA 5 mg & 10 mg Filmtabletten;
Tofacitinib EG 5 mg & 10 mg filmomhulde Tabletten;
Tofacitinib EG 5 mg & 10 mg comprimés pelliculés;
Tofacitinib STADA;
Tofacitinib STADA 5 mg & 10 mg comprimidos recubiertos con película EFG;
TOFACITINIB STADA 5 mg & 10 mg, comprimé pelliculé;
Tofacitinib/STADA;
Tofacitinib STADA 5 mg & 10 mg filmom obložene tablete;
Tofacitinib STADA 5 mg & 10 mg filmtabletta;
Tofacitinib STADA 5 mg & 10 mg film-coated tablets;
Tofacitinib STADA 5 mg & 10 mg filmuhúðuð tafla;
Tofacitinib EG;
Tofacitinib STADA 5 mg & 10 mg, filmomhulde Tabletten;
Tofacitinib STADA 5 mg & 10 mg comprimate filmate;
Tofacitinib STADA 5 mg & 10 mg filmdragerade tabletter;
Tofacitinib STADA 5 mg & 10 mg filmsko obložene tablete;
Tofacitinib STADA 5 mg & 10 mg filmom obalené tablety;
Tofacitinib STADA Arzneimittel AG 5 mg & 10 mg tabletti, kalvopäällysteinen;
Tofacitinib AL 5 mg & 10 mg Filmtabletten

(Tofacitinib)

This is a summary of the risk management plan (RMP) for Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL. The RMP details important risks of Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL, how these risks can be minimised, and how more information will be obtained about Tofacitinib STADA's/ Tofacitinib EG's/ TOFACITINIB STADA's/ Tofacitinib/STADA's/ Tofacitinib STADA Arzneimittel AG's/ Tofacitinib AL's risks and uncertainties (missing information).

Tofacitinib STADA's/ Tofacitinib EG's/ TOFACITINIB STADA's/ Tofacitinib/STADA's/ Tofacitinib STADA Arzneimittel AG's/ Tofacitinib AL's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL should be used.

Important new concerns or changes to the current ones will be included in updates of Tofacitinib STADA's/ Tofacitinib EG's/ TOFACITINIB STADA's/ Tofacitinib/STADA's/ Tofacitinib STADA Arzneimittel AG's/ Tofacitinib AL's RMP.

I. The medicine and what it is used for

Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL is authorised for the treatment of adults with moderate to severe active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderately to severely active ulcerative colitis, and of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis (see SmPC for the full indication). It contains tofacitinib as the active substance and it is given by oral route of administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL, together with measures to minimise such risks and the proposed studies for learning more about Tofacitinib STADA's/ Tofacitinib EG's/ TOFACITINIB STADA's/ Tofacitinib/STADA's/ Tofacitinib STADA Arzneimittel AG's/ Tofacitinib AL's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In the case of Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL, these measures are supplemented with *additional risk minimisation measures* mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• Venous thromboembolic events (DVT/PE) • Serious and other important infections • HZ reactivation • Lung cancer • Lymphoma • Myocardial infarction • Decrease in Hgb levels and anaemia • NMSC • Transaminase elevation and potential for DILI • Higher incidence and severity of AEs in the elderly
Important potential risks	• Malignancy • Cardiovascular risk (excl MI) • GI perforation • ILD • PML • All-cause mortality • Fractures • Increased risk of AEs when tofacitinib is administered in combination with MTX in RA or PsA patients • Primary viral infection following live vaccination
Missing information	• Effects on pregnancy and the foetus • Use in breastfeeding • Effect on vaccination efficacy and the use of live/attenuated vaccines • Use in patients with mild, moderate, or severe hepatic impairment • Use in patients with moderate or severe renal impairment • Use in patients with evidence of hepatitis B or hepatitis C infection • Use in patients with malignancy • Long-term safety in pJIA patients and juvenile PsA patients (e.g., growth or development disturbances)

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

Important identified risk: Venous thromboembolic events (DVT/PE)	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 4.8, 5.1 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important identified risk: Serious and other important infections	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.2, 4.3, 4.4, 4.8, 5.1 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important identified risk: HZ reactivation	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 4.8 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals

Important identified risk: Lung cancer	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 4.8, 5.1 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important identified risk: Lymphoma	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 4.8, 5.1 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important identified risk: Myocardial infarction	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 4.8, 5.1 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important identified risk: Decrease in Hgb levels and anaemia	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.2, 4.4, 4.8 Additional risk minimisation measures: • Guide for Healthcare Professionals • Prescriber Checklist

Important identified risk: NMSC	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 4.8 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important identified risk: Transaminase elevation and potential for DILI	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 4.8 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important identified risk: Higher incidence and severity of AEs in the elderly	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.2, 4.4, 4.8, 5.1 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important potential risk: Malignancy	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 5.1 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important potential risk: Cardiovascular risk (excl MI)	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 5.1 Additional risk minimisation measures: • Guide for Healthcare Professionals • Prescriber Checklist

Important potential risk: GI perforation	
Risk minimisation measures	Routine risk minimisation measures: SmPC section 4.4 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important potential risk: ILD	
Risk minimisation measures	Routine risk minimisation measures: SmPC section 4.4 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Important potential risk: All-cause mortality	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.4, 5.1 Additional risk minimisation measures: • Guide for Healthcare Professionals • Prescriber Checklist

Important potential risk: Increased risk of AEs when tofacitinib is administered in combination with MTX in RA or PsA patients	
Risk minimisation measures	Routine risk minimisation measures: SmPC section 4.4 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals

Important potential risk: Primary viral infection following live vaccination	
Risk minimisation measures	Routine risk minimisation measures: SmPC section 4.4 Additional risk minimisation measures: • Guide for Healthcare Professionals • Prescriber Checklist

Missing information: Effects on pregnancy and the foetus	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.3, 4.6 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Missing information: Use in breastfeeding	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.3, 4.6 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Missing information: Effect on vaccination efficacy and the use of live/attenuated vaccines	
Risk minimisation measures	Routine risk minimisation measures: SmPC section 4.4 Additional risk minimisation measures: • Patient Card • Guide for Healthcare Professionals • Prescriber Checklist

Missing information: Use in patients with mild, moderate, or severe hepatic impairment	
Risk minimisation measures	Routine risk minimisation measures: SmPC sections 4.2, 4.3, 5.2 Additional risk minimisation measures: • Guide for Healthcare Professionals • Prescriber Checklist

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Tofacitinib STADA/ Tofacitinib EG/ TOFACITINIB STADA/ Tofacitinib/STADA/ Tofacitinib STADA Arzneimittel AG/ Tofacitinib AL.